-
“Chemo brain” may be an inaccurate descriptor of cognitive issues. Fatigue is a key contributor to cognitive problems. Interventions to reduce stress and fatigue may alleviate postchemotherapy neurocognitive problems. SAN ANTONIO — Women undergoing chemotherapy who experience cognitive...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, women, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, fatigue, Dr. Bernadine Cimprich, chemo brain
-
HER2 mutations occurred separately from HER2 gene amplification and DNA sequencing is required to detect them. HER2 mutations are rare but can be immediately treated with existing drugs. Phase II study using neratinib to treat HER2 mutations is under way. SAN ANTONIO — An analysis of data from...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, genetics, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, therapeutic target, neratinib, breast cancer genome, Dr. Ron Bose, HER2 mutations
-
Safety profile was consistent with previous trials of bevacizumab. More understanding of triple-negative breast cancer is still needed. Final overall survival data are expected in 2013. SAN ANTONIO — Patients who received one year of bevacizumab in addition to chemotherapy for the postsurgical...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, triple-negative breast cancer, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, bevacizumab, Dr. David Cameron, BEATRICE study
-
Eribulin showed trend toward improved overall survival versus capecitabine. Eribulin showed greater activity in certain subsets of patients. Researchers are still gathering quality-of-life data. SAN ANTONIO — A phase III multicenter study of eribulin mesylate in women with previously treated metastatic...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, metastatic breast cancer, capecitabine, Dr. Peter A. Kaufman, eribulin
-
High number of patients who received one year of trastuzumab were disease-free eight years later. One year of trastuzumab showed superior safety profile with no major cardiac toxicity. Efficacy of two years of trastuzumab treatment was comparable to one year. SAN ANTONIO — One year of adjuvant...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, Trastuzumab, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, Standard of Care, HERA trial, Dr. Martine J. Piccart
-
Disease-free and overall survival improved with postsurgical chemotherapy. Patients with ER-negative breast cancers were most responsive to treatment. SAN ANTONIO — Chemotherapy after surgery, or adjuvant chemotherapy, led to higher rates of disease-free and overall survival for women with isolated...
Posted to
News
by
AACR News
on
Thu, Dec 6 2012
Filed under:
Filed under: Press Releases, Treatment, Breast Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, overall survival, Dr. Stefan Aebi, disease-free survival, adjuvant chemotherapy
-
Finding was confined to those with triple-negative and luminal-type breast cancer. Better outcomes seen for young women with luminal A-like tumors who achieved a pathological complete response compared with those who did not. Neoadjuvant chemotherapy needed for young women, even those with HR-positive...
Posted to
News
by
AACR News
on
Thu, Dec 6 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, women, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, triple-negative breast cancer, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, neoadjuvant chemotherapy, luminal A, Dr. Sibylle Loibl, HER2-negative, HR-positive, young women
-
Residual tumor cells are found in up to 70 percent of these patients. Multiple types of potentially actionable somatic genetic changes in the residual cancer remain in the breast after treatment. Molecular information from the tumor remaining after neoadjuvant therapy could lead to targeted therapies...
Posted to
News
by
AACR News
on
Thu, Dec 6 2012
Filed under:
Filed under: Press Releases, Research, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, genetics, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, triple-negative breast cancer, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, neoadjuvant chemotherapy, Dr. Justin M. Balko, personalized treatment
-
Low local relapse rates were observed after breast cancer radiotherapy. Lower total radiation dose in fewer, larger fractions was effective. Three-week, 15-fraction schedule is the standard of care in the United Kingdom. SAN ANTONIO — Appropriately dosed hypofractionated radiotherapy was gentle...
Posted to
News
by
AACR News
on
Thu, Dec 6 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, radiotherapy, press conference, Radiation therapy, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, John Yarnold, fraction schedule, START trials, hypofractionated radiotherapy
-
HDAC inhibitors indirectly caused DNA damage and impaired DNA repair. Cellular conditions created by HDAC inhibition mimicked those in BRCA1-mutated breast cancer cells. Findings could have implications for hard-to-treat triple-negative breast cancer. SAN ANTONIO — In-vitro exposure to an HDAC...
Posted to
News
by
AACR News
on
Thu, Dec 6 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, triple-negative breast cancer, press conference, HDAC inhibitor, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, PARP inhibitors, BRCA1, Dr. Kapil N. Bhalla
-
Presurgery chemotherapy eradicated lymph node disease in 40 percent of cases. Sentinel lymph node surgery after chemotherapy correctly identified nodal status in 91 percent of patients. False negative rate of SNL surgery was 12.6 percent. Once chemotherapy is completed, this surgery may be reasonable...
Posted to
News
by
AACR News
on
Wed, Dec 5 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, neoadjuvant chemotherapy, nodal staging, Dr. Judy C. Boughey, sentinel lymph node surgery
-
Combination improved progression-free survival and was well tolerated. Investigational agent is an oral selective inhibitor of cyclin-dependent kinase 4/6. SAN ANTONIO — The combination of the investigational agent PD 0332991 and letrozole significantly improved median progression-free survival...
Posted to
News
by
AACR News
on
Wed, Dec 5 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, Letrozole, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, investigational agent, Dr. Richard S. Finn, PD 0332991
-
Greatest additional benefit was seen in the second decade after diagnosis. Findings are directly relevant to women taking tamoxifen. Women on other ER-positive breast cancer endocrine treatments may benefit. SAN ANTONIO — Ten years of adjuvant treatment with tamoxifen provided women with estrogen...
Posted to
News
by
AACR News
on
Wed, Dec 5 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, tamoxifen, ER-positive breast cancer, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, ATLAS trial, Dr. Christina Davies
-
Data from 2002 to 2007 show a consistent disparity. Black women were 12 percent less likely to receive newer surgical practice. More efforts are needed to widely implement improved techniques. SAN ANTONIO — Black women with breast cancer were 12 percent less likely than white women with the disease...
Posted to
News
by
AACR News
on
Wed, Dec 5 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, Disparities, cancer health disparities, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, sentinel lymph node biopsy, Dr. Dalliah Mashon Black
-
Improved survival seen with 500-mg dose versus 250-mg dose in patients with ER-positive metastatic disease. Toxicity profiles were similar between dosage groups. SAN ANTONIO — Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced...
Posted to
News
by
AACR News
on
Wed, Dec 5 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, Dr. Angelo Di Leo, fulvestrant, CONFIRM trial